Enalaprilat Injection Rx
Generic Name and Formulations:
Enalaprilat 1.25mg/mL; soln for IV inj.
Various generic manufacturers
Indications for Enalaprilat Injection:
To reduce blood pressure when oral therapy is not practical.
Give by IV inj over 5 minutes (administer over a longer period of time [up to 1 hour] in patients at risk for excessive hypotension). 1.25mg every 6 hours; max 20mg/day. Concomitant diuretics or CrCl≤30mL/min: initially 0.625mg; if inadequate response after 1 hour, may give additional 0.625mg dose; additional doses of 1.25mg may be given every 6 hours thereafter.
History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).
Renal or hepatic impairment. Salt/volume depletion. Severe CHF. Renal artery or aortic stenosis. Hypertrophic cardiomyopathy. Monitor for neutropenia in renal or collagen vascular disease. Monitor for hyperkalemia in diabetics. Dialysis. Surgery. Discontinue if laryngeal edema, angioedema, marked elevations of liver enzymes or jaundice occurs. Black patients may have higher risk of angioedema than non-black patients. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers.
Hypotension with diuretics. Hyperkalemia with K+-sparing diuretics or K+ supplements. May increase lithium levels. May be antagonized by NSAIDS.
Headache, orthostatic hypotension, asthenia, hyperkalemia, renal impairment, nausea, cough; angioedema, liver dysfunction, blood dyscrasias (rare).
Formerly known under the brand name Vasotec.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|